19.67
-0.02(-0.10%)
Currency In USD
| Previous Close | 19.69 |
| Open | 19.55 |
| Day High | 19.87 |
| Day Low | 19.19 |
| 52-Week High | 25.48 |
| 52-Week Low | 10.57 |
| Volume | 821,581 |
| Average Volume | 1.72M |
| Market Cap | 2.88B |
| PE | -6.73 |
| EPS | -2.92 |
| Moving Average 50 Days | 16.69 |
| Moving Average 200 Days | 15.03 |
| Change | -0.03 |
If you invested $1000 in Denali Therapeutics Inc. (DNLI) since IPO date, it would be worth $917.02 as of December 09, 2025 at a share price of $19.67. Whereas If you bought $1000 worth of Denali Therapeutics Inc. (DNLI) shares 5 years ago, it would be worth $257.7 as of December 09, 2025 at a share price of $19.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
4 hours ago
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and, in lieu of common stock to certain investors, p
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
GlobeNewswire Inc.
Dec 04, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales o
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
GlobeNewswire Inc.
Oct 13, 2025 8:01 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics License Application (BLA) seek